HK1042518B - 對前列腺特異性抗原(psa)的免疫應答的產生 - Google Patents

對前列腺特異性抗原(psa)的免疫應答的產生

Info

Publication number
HK1042518B
HK1042518B HK02103565.7A HK02103565A HK1042518B HK 1042518 B HK1042518 B HK 1042518B HK 02103565 A HK02103565 A HK 02103565A HK 1042518 B HK1042518 B HK 1042518B
Authority
HK
Hong Kong
Prior art keywords
psa
host
virus vector
additional
specific antigen
Prior art date
Application number
HK02103565.7A
Other languages
English (en)
Other versions
HK1042518A1 (en
Inventor
Jeffrey Schlom
Dennis Panicali
Original Assignee
The Government Of The United States Of America As Represented By The Secretary Dept Of Health And Hu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1042518(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Government Of The United States Of America As Represented By The Secretary Dept Of Health And Hu filed Critical The Government Of The United States Of America As Represented By The Secretary Dept Of Health And Hu
Publication of HK1042518A1 publication Critical patent/HK1042518A1/xx
Publication of HK1042518B publication Critical patent/HK1042518B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK02103565.7A 1995-07-10 2002-05-11 對前列腺特異性抗原(psa)的免疫應答的產生 HK1042518B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/500,306 US6165460A (en) 1995-07-10 1995-07-10 Generation of immune responses to prostate-specific antigen (PSA)

Publications (2)

Publication Number Publication Date
HK1042518A1 HK1042518A1 (en) 2002-08-16
HK1042518B true HK1042518B (zh) 2009-04-17

Family

ID=23988841

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103565.7A HK1042518B (zh) 1995-07-10 2002-05-11 對前列腺特異性抗原(psa)的免疫應答的產生

Country Status (11)

Country Link
US (2) US6165460A (zh)
EP (2) EP1162272B8 (zh)
JP (3) JP4633867B2 (zh)
AT (2) ATE413459T1 (zh)
CA (1) CA2226436C (zh)
DE (2) DE69618601T2 (zh)
DK (2) DK1162272T3 (zh)
ES (2) ES2320089T3 (zh)
HK (1) HK1042518B (zh)
PT (2) PT840791E (zh)
WO (1) WO1997003203A2 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699475B1 (en) * 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7816087B2 (en) 2001-11-14 2010-10-19 The United States Of America As Represented By The Department Of Health And Human Services Gene expressed in prostate cancer and methods of use
DE60304040T2 (de) * 2002-06-11 2006-09-28 Merck Patent Gmbh Methode zur identifizierung und eliminierung von t-zell epitopen
DE10230893A1 (de) * 2002-06-26 2004-01-15 Dr. Fischer Ag Verfahren zur Eigenschaftsbestimmung und/oder Klassifikation von zirkulierenden Macrophagen und/oder peripheren blutmononuclearen Zellen sowie Analyseanordnung zur Durchführung des Verfahrens
US20040170646A1 (en) * 2002-12-13 2004-09-02 Aventis Pasteur, Inc. Production of ALVAC on avian embryonic stem cells
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
EP1660664A4 (en) * 2003-08-21 2008-02-13 Virax Dev Pty Ltd POXVIRUS VECTOR ENCODING SPECIFIC PROSTATE ANTIGENS FOR THE TREATMENT OF PROSTATE CANCER
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
JP2008546788A (ja) * 2005-06-21 2008-12-25 サイト パルス サイエンシズ、インコーポレイテッド 前立腺癌に対するワクチンに関する方法及び組成物
EP2397854B1 (en) 2006-03-14 2014-06-04 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
DK2918598T3 (en) 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
KR20160065985A (ko) * 2007-10-18 2016-06-09 버베리안 노딕 에이/에스 전립선 암 치료를 위한 ｍｖａ의 용도
EP2352520B1 (en) * 2008-10-31 2015-08-05 TremRx, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
HUE028582T2 (en) 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health&Science University Methods for producing an immune response to tuberculosis
WO2012019125A2 (en) 2010-08-06 2012-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
JPWO2014097762A1 (ja) * 2012-12-20 2017-01-12 国立大学法人 熊本大学 高病原性トリインフルエンザに対する抗体
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
CN107849117B (zh) 2015-06-05 2022-08-26 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
EP3331554B1 (en) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
ATE248924T1 (de) * 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)

Also Published As

Publication number Publication date
JPH11509199A (ja) 1999-08-17
EP1162272B1 (en) 2008-11-05
ATE413459T1 (de) 2008-11-15
CA2226436A1 (en) 1997-01-30
EP1162272A2 (en) 2001-12-12
JP2008285492A (ja) 2008-11-27
US7598225B1 (en) 2009-10-06
DK1162272T3 (da) 2009-03-09
JP2006197938A (ja) 2006-08-03
US6165460A (en) 2000-12-26
PT840791E (pt) 2002-06-28
DE69637738D1 (de) 2008-12-18
WO1997003203A3 (en) 1997-04-17
EP1162272B8 (en) 2010-03-10
ES2172669T3 (es) 2002-10-01
EP1162272A3 (en) 2004-07-14
ES2320089T3 (es) 2009-05-19
DE69618601D1 (de) 2002-02-21
PT1162272E (pt) 2009-02-16
DK0840791T3 (da) 2002-03-18
HK1042518A1 (en) 2002-08-16
EP0840791A2 (en) 1998-05-13
ATE212058T1 (de) 2002-02-15
CA2226436C (en) 2006-11-07
DE69618601T2 (de) 2002-08-08
WO1997003203A2 (en) 1997-01-30
JP4633867B2 (ja) 2011-02-16
EP0840791B1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
EP1162272B8 (en) Generation of immune responses to prostate specific antigen (PSA)
ATE475668T1 (de) Immunisierung durch impfung von dns transkriptionseinheit
IL141588A0 (en) Method for down-regulating osteoprotegerin ligand activity
EP0794797A4 (en) METHODS AND EQUIPMENT FOR IMMUNIZING A HOST BY ADMINISTERING NAKED POLYNUCLEOTIDES ENCODING ANTIGEN PEPTIDES
AU6117696A (en) Nucleic acid respiratory syncytial virus vaccines
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
DK0892054T3 (da) Clostridium perfringens-vaccine
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
DE69937258D1 (de) Genetische impstoffe mit adjuvans
AU7903594A (en) Antigens containing metastable bonds
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.
SI1227840T1 (sl) Genetske vakcine z adjuvansom
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
CHRG Changes in the register

Free format text: CORRECTION OF THE TITLE OF INVENTION FROM GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (SPA) TO GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)

PE Patent expired

Effective date: 20160625